Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Acta Biomater. 2020 Aug 25;115:418–431. doi: 10.1016/j.actbio.2020.08.032

Figure 2. In vitro biofilm studies show co-delivery of farnesol and myricetin synergistically improved anti-biofilm efficacy and maintained neutral pH in developing biofilms.

Figure 2.

A) Scheme showing the treatment regimen used with developing S. mutans biofilms grown in vitro on saliva-coated hydroxyapatite (sHA) disks.B) Biofilm dry weights obtained for biofilms formed on sHA disks for each treatment show significant reduction (~97-99%) for NPCs co-loaded with farnesol and myricetin. C) Log colony forming unit per mL data for NPCs co-loaded with farnesol and myricetin show ~2-3 log reduction compared to controls. Grey dashed line indicates the log CFU/mL limit of detection for this assay. Dry weight and CFU/mL data shown as mean ± standard deviation from n=2-4 independent measurements. **p<0.01 and ****p<0.001 from One-way ANOVA with Dunnett’s multiple comparisons test (versus PBS control). D) Plots showing changes in pH over time for developing S. mutans biofilms treated with control or experimental groups listed. pH data shown as mean ± standard deviation from n = 2 measurements per group at each experimental time point (i.e., t = 0, 20, 30, and 44 hours).